Multicentric, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12-MonthPeriod, in Patients with Severe IgE-mediated Asthma Inadequately Controlled with High Doses of Corticosteroids. MEXIC Study

Trial Profile

Multicentric, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12-MonthPeriod, in Patients with Severe IgE-mediated Asthma Inadequately Controlled with High Doses of Corticosteroids. MEXIC Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 May 2017

At a glance

  • Drugs Omalizumab (Primary) ; Budesonide; Formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms MEXIC
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 28 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Nov 2016 as reported by ClinicalTrilas.gov record.
    • 20 Mar 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2016 as reported by ClinicalTrilas.gov record.
    • 20 Jan 2015 Planned End Date changed from 1 Jul 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top